Eribulin Not Superior to Capecitabine for Previously Treated Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, researchers have found that eribulin mesylate is not superior to capecitabine for the treatment of patients with locally advanced or metastatic breast cancer who were previously treated with an anthracycline and a taxane.
In this open label, phase 3 study, researchers sought to compare the efficacy of eribulin mesylate versus capecitabine for advanced/metastatic breast cancer.
Researchers enrolled 1,102 women with metastatic breast cancer who had previously received anthracycline- and taxane-based therapy and randomly assigned them to receive either eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced disease.
Results showed median overall survival times of 15.9 months and 14.5 months for eribulin and capecitabine, respectively (HR = 0.88; 95% CI: 0.77 - 1.00; P = 0.056). Median progression-free survival times were 4.1 months for the eribulin arm and 4.2 months for the capecitabine arm (HR = 1.08; 95% CI: 0.93 - 1.25; P = 0.30).
In addition, the eribulin group had an 11.0% objective response rate compared with 11.5% in the capecitabine group. Researchers also found that both treatments had manageable safety profiles.
Eribulin mesylate is not superior to capecitabine for the treatment of locally advanced or metastatic breast cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- St John's Wort and Cancer
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC
- Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation
- Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC
- Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC